$71.2301
0.0601[0.08%]
Last update: 12:21PM Get Real Time Here
Axsome Therapeutics
(NASDAQ:AXSM)Latest News for Axsome Therapeutics Stock (NASDAQ:AXSM)
Axsome Therapeutics Stock (NASDAQ: AXSM)
Categories: All
Wednesday, April 10, 2024
Tuesday, April 02, 2024
Monday, April 01, 2024
Thursday, March 28, 2024
Tuesday, March 26, 2024
- Truist Securities Maintains Buy on Axsome Therapeutics, Maintains $150 Price TargetBenzinga Newsdesk - Mar 26, 2024, 9:23AM
- Tesla To $120? Here Are 10 Top Analyst Forecasts For TuesdayAvi Kapoor - Mar 26, 2024, 8:30AM
- RBC Capital Maintains Outperform on Axsome Therapeutics, Raises Price Target to $128Benzinga Newsdesk - Mar 26, 2024, 8:09AM
- Citigroup Maintains Buy on Axsome Therapeutics, Raises Price Target to $127Benzinga Newsdesk - Mar 26, 2024, 7:34AM
- HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Raises Price Target to $190Benzinga Newsdesk - Mar 26, 2024, 6:15AM
Monday, March 25, 2024
- What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday?Vandana Singh - Mar 25, 2024, 12:03PM
- Axsome Therapeutics shares are trading higher the company's AXS-12 achieved primary endpoint in the SYMPHONY phase 3 trial in narcolepsy.Benzinga Newsdesk - Mar 25, 2024, 6:41AM
- Axsome Therapeutics' AXS-12 (Reboxetine) Achieved The Primary Endpoint And Significantly Reduced The Frequency Of Cataplexy Attacks As Compared To Placebo In Narcolepsy Patients In SYMPHONY Phase 3 TrialBenzinga Newsdesk - Mar 25, 2024, 6:32AM
Wednesday, March 20, 2024
Tuesday, March 19, 2024
- What Analysts Are Saying About Axsome Therapeutics StockBenzinga Insights - Mar 19, 2024, 9:01AM
- Axsome Therapeutics Announced The First Patient Has Been Dosed In PARADIGM Phase 3 Trial Of Solriamfetol, An Investigational Treatment For Major Depressive DisorderBenzinga Newsdesk - Mar 19, 2024, 7:01AM
- Baird Initiates Coverage On Axsome Therapeutics with Outperform Rating, Announces Price Target of $108Benzinga Newsdesk - Mar 19, 2024, 4:48AM
Monday, March 04, 2024
Tuesday, February 27, 2024
Wednesday, February 21, 2024
- Guggenheim Maintains Buy on Axsome Therapeutics, Raises Price Target to $125Benzinga Newsdesk - Feb 21, 2024, 12:57PM
- RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $123Benzinga Newsdesk - Feb 21, 2024, 10:09AM
- Cantor Fitzgerald Maintains Overweight on Axsome Therapeutics, Lowers Price Target to $103Benzinga Newsdesk - Feb 21, 2024, 9:38AM
Tuesday, February 20, 2024
- CORRECTION: Axsome Therapeutics Q4 Adjusted EPS $(0.73) Beats $(1.15) Estimate, Sales $71.53M Beat $67.69M EstimateBenzinga Newsdesk - Feb 20, 2024, 7:03PM
- Neurology-Focused Axsome Therapeutics Reports Deeper Than Expected Q4 Loss, Updates Upcoming Pipeline MilestonesVandana Singh - Feb 20, 2024, 1:05PM
- Cantor Fitzgerald Reiterates Overweight on Axsome Therapeutics, Maintains $108 Price TargetBenzinga Newsdesk - Feb 20, 2024, 12:32PM
- Axsome Therapeutics shares are trading lower after the company reported worse-than-expected Q4 EPS results.Benzinga Newsdesk - Feb 20, 2024, 11:55AM
- Earnings Scheduled For February 20, 2024Benzinga Insights - Feb 20, 2024, 6:52AM
Monday, February 19, 2024
Friday, February 16, 2024
Tuesday, February 06, 2024
- UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive CatalystVandana Singh - Feb 6, 2024, 2:19PM
- The Latest Analyst Ratings For Axsome TherapeuticsBenzinga Insights - Feb 6, 2024, 8:00AM
- UBS Initiates Coverage On Axsome Therapeutics with Buy Rating, Announces Price Target of $111Benzinga Newsdesk - Feb 6, 2024, 7:49AM
Friday, January 26, 2024
Thursday, January 25, 2024
Monday, January 22, 2024
Tuesday, January 16, 2024
Thursday, January 04, 2024
- Axsome Therapeutics shares are trading higher after the company reported preliminary Q4 net product revenue above estimates.Benzinga Newsdesk - Jan 4, 2024, 10:53AM
- Axsome Therapeutics Expects Preliminary 4Q Net Product Revenue Of $71M Vs. $66.44M Estimate; Expects FY23 Net Product Revenue Of $204M Vs. $265.95M EstimateBenzinga Newsdesk - Jan 4, 2024, 7:16AM